Related Experiment Videos

Switching HIV-1 protease inhibitor therapy: which? When? And why?

J M Guardiola, P Domingo, G Vazquez

Archives of Internal Medicine

|February 2, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men.

HIV medicine·2024

Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function.

Biochemical pharmacology·2023

Gender differences in workplace violence against physicians and nurses in Latin America: a survey from the Interamerican Society of Cardiology.

Public health·2023

[Emergency detection of HIV infection in patients consulting for conditions potentially related to occult infection: Initial results of the "Urgències VIHgila" program].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).

Open forum infectious diseases·2022

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.

The Journal of antimicrobial chemotherapy·2020

See all related articles